Volume | 97,173 |
|
|||||
News | - | ||||||
Day High | 2.50 | Low High |
|||||
Day Low | 2.24 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
BeyondSpring Inc | BYSI | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
2.29 | 2.24 | 2.50 | 2.43 | 2.29 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
659 | 97,173 | $ 2.43 | $ 236,434 | - | 0.6534 - 4.00 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
16:53:00 | 20 | $ 2.36 | USD |
BeyondSpring Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
94.58M | 38.92M | - | 1.35M | -33.28M | -0.86 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
BeyondSpring News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BYSI Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.80 | 2.50 | 1.79 | 2.01 | 83,202 | 0.63 | 35.00% |
1 Month | 3.65 | 3.69 | 1.76 | 2.61 | 105,763 | -1.22 | -33.42% |
3 Months | 0.9998 | 4.00 | 0.97 | 2.77 | 238,594 | 1.43 | 143.05% |
6 Months | 1.03 | 4.00 | 0.7777 | 2.43 | 136,002 | 1.40 | 135.92% |
1 Year | 1.05 | 4.00 | 0.6534 | 1.99 | 98,693 | 1.38 | 131.43% |
3 Years | 10.23 | 33.00 | 0.542 | 13.33 | 671,122 | -7.80 | -76.25% |
5 Years | 14.54 | 33.00 | 0.542 | 13.33 | 459,136 | -12.11 | -83.29% |
BeyondSpring Description
BeyondSpring Inc is engaged in clinical stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. The Company has created Plinabulin which is marine derived small-molecule with a number of distinct biological activities that may provide multiple therapeutic opportunities. Plinabulin has increased the survival of neutrophils, a type of white blood cell important in the prevention of bacterial infections. The Company has a scalable business model integrating clinical resources in the United States and China. |